Jean Claude Sadik

Dr. Jean Claude Sadik

Head of the Service de Neuroradiologie diagnostique, Hôpital Fondation Rothschild, 29 rue Manin, 75019 Paris, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Life
Verified
Journal Article
Open access
PDF file
Jean Claude SadikJean Claude Sadik
Jean Claude Sadik
Dragos Catalin JianuDragos Catalin Jianu
Dragos Catalin Jianu
RSRaphaël Sadik
Raphaël Sadik
YPYvonne Purcell
Yvonne Purcell
NNNatalia Novaes
Natalia Novaes
JSJulien Savatovsky
Julien Savatovsky
Cerebral venous thrombosis is a rare cause of stroke. Imaging is essential for diagnosis. Although digital subtraction angiography is still considered by many to be the gold standard, it no longer plays a significant role in the diagnosis of cerebral venous thrombosis. MRI, which allows for imaging the parenchyma, vessels and clots, and CT are the reference techniques. CT is useful in case of contraindication to MRI. After presenting the radio-anatomy for MRI, we present the different MRI and CT acquisitions, their pitfalls and their limitations in the diagnosis of cerebral venous thrombosis.

22 July 2022 in Life
Verified
Journal Article
Open access
PDF file
NNNatalia Pelizari Novaes
Natalia Pelizari Novaes
RSRaphaël Sadik
Raphaël Sadik
Jean Claude SadikJean Claude Sadik
Jean Claude Sadik
MOMichaël Obadia
Michaël Obadia
Cerebral venous thrombosis (CVT) is a rare type of stroke that may cause an intracranial hypertension syndrome as well as focal neurological deficits due to venous infarcts. MRI with venography is the method of choice for diagnosis, and treatment with anticoagulants should be promptly started. CVT incidence has increased in COVID-19-infected patients due to a hypercoagulability state and endothelial inflammation. CVT following COVID-19 vaccination could be related to vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe complication that should be promptly identified because of its high mortality rate. Platelet count, D-dimer and PF4 antibodies should be dosed. Treatment with non-heparin anticoagulants and immunoglobulin could improve recuperation. Development of headache associated with seizures, impaired consciousness or focal signs should raise immediate suspicion of CVT. In patients who received a COVID-19 adenovirus-vector vaccine presenting thromboembolic events, VITT should be suspected and rapidly treated. Nevertheless, vaccination benefits clearly outweigh risks and should be continued.